Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial

A definitive conclusion regarding the value of low-dose extended duration adjuvant interferon-alpha therapy in the treatment of malignant melanoma is only possible once data on health-related quality of life (HRQoL) and costs have been considered. This trial randomised 674 patients to interferon alp...

Descripción completa

Detalles Bibliográficos
Autores principales: Dixon, S, Walters, S J, Turner, L, Hancock, B W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361187/
https://www.ncbi.nlm.nih.gov/pubmed/16449995
http://dx.doi.org/10.1038/sj.bjc.6602973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361187/
https://www.ncbi.nlm.nih.gov/pubmed/16449995
http://dx.doi.org/10.1038/sj.bjc.6602973

Ejemplares similares